Thank you for donating!

You can donate using the following services.

Newly Diagnosed?

When you, your child or loved one is diagnosed with Niemann-Pick disease it can have a profound effect on your whole family. For many people, a diagnosis of Niemann-Pick disease does not happen instantly and can come at the end of weeks or months of tests and investigations.

In many cases this can be the point from which you begin to contemplate the future…

shot-468

During this period of adjustment you and your family may face what feels like a never-ending round of appointments as you begin to meet with the many professionals who will form a network of care around you or your loved one and you may find yourself having to tell your story time and time again. Hearing the news that your child or family member has a life-affecting disease, but that no one can tell you the exact path the disease will take, may make you feel that your hopes and dreams have been shattered.

Where Do I Start?

At this time there is a lot to think about. Diagnosis comes at a point when you may not be capable of thinking clearly or taking information in.

We have people dedicated to support you to digest all the information:

  • Our Families Officer, who can offer advice on a range of topics including education and social welfare.
  • Our Clinical Nurse Specialist who provides advice and information regarding all aspects of Niemann-Pick Disease.
  • And our entire Central Office Team, who are always available to provide information about the disease and all aspects of the support we provide for families.

If you would like to speak to someone about any aspect of the disease:

  • Call the 24-hour helpline on 0191 415 0693
  • Send us an email at info@npuk.org

Latest news

15.03.19

CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol® Cyclo™ in Alzheimer’s Disease

ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.

Read more

11.03.19

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC)

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).

Read more
View all news Subscribe